<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05074433</url>
  </required_header>
  <id_info>
    <org_study_id>R10933-10987-COV-2176</org_study_id>
    <secondary_id>2021-005222-14</secondary_id>
    <nct_id>NCT05074433</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Efficacy and Safety of Casirivimab+Imdevimab (Monoclonal Antibodies) for Prevention of COVID-19 in Immunocompromised Adolescents and Adults</brief_title>
  <official_title>A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regeneron Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to evaluate the effect of casirivimab+imdevimab,&#xD;
      compared with placebo, in preventing symptomatic SARS-CoV-2 infection in immunocompromised&#xD;
      participants.&#xD;
&#xD;
      The secondary objectives of the study are:&#xD;
&#xD;
        -  To evaluate the safety and tolerability of repeated SC injections of&#xD;
           casirivimab+imdevimab in the study population&#xD;
&#xD;
        -  To characterize concentrations of casirivimab and imdevimab in serum over time&#xD;
&#xD;
        -  To assess the immunogenicity of casirivimab and imdevimab&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 25, 2021</start_date>
  <completion_date type="Anticipated">June 26, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 3, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative incidence of symptomatic (broad term), RT-PCR-confirmed SARS-CoV-2 infection cases</measure>
    <time_frame>Up to 169 Days</time_frame>
    <description>Efficacy Assessment Period (EAP)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with grade ≥3 treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>Up to 253 Days</time_frame>
    <description>EAP and follow-up period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with TEAEs leading to study drug discontinuation</measure>
    <time_frame>Up to 253 Days</time_frame>
    <description>EAP and follow-up period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with treatment-emergent serious adverse events (SAEs)</measure>
    <time_frame>Up to 253 Days</time_frame>
    <description>EAP and follow-up period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events of special interest (AESIs)</measure>
    <time_frame>Up to 169 Days</time_frame>
    <description>EAP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of each mAb over time</measure>
    <time_frame>Up to 253 Days</time_frame>
    <description>As applicable to the treatment arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and titer of anti-drug antibodies (ADA) over time</measure>
    <time_frame>Up to 253 Days</time_frame>
    <description>As applicable to the treatment arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of neutralizing antibodies (NAb) to each mAb over time</measure>
    <time_frame>Up to 253 Days</time_frame>
    <description>As applicable to the treatment arm</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">8752</enrollment>
  <condition>Immunocompromised</condition>
  <arm_group>
    <arm_group_label>casirivimab+imdevimab Initial + Q4W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Initial subcutaneous (SC) dose, then SC dose every 4 weeks (Q4W)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>casirivimab+imdevimab Q4W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SC dose Q4W</description>
  </arm_group>
  <arm_group>
    <arm_group_label>casirivimab+imdevimab Q12W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SC dose every 12 weeks (Q12W)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>SC dose Q4W</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>casirivimab+imdevimab</intervention_name>
    <description>Co-administered sequentially subcutaneous (SC)</description>
    <arm_group_label>casirivimab+imdevimab Initial + Q4W</arm_group_label>
    <arm_group_label>casirivimab+imdevimab Q12W</arm_group_label>
    <arm_group_label>casirivimab+imdevimab Q4W</arm_group_label>
    <other_name>REGN-COV2</other_name>
    <other_name>REGN10933</other_name>
    <other_name>REGN10987</other_name>
    <other_name>REGEN-COV™</other_name>
    <other_name>Ronapreve™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Meets ≥1 of the following criteria:&#xD;
&#xD;
               -  Is immunocompromised, including people with transplant, who have cancer, primary&#xD;
                  immunodeficiencies, HIV, rheumatological disease, autoimmune disease, multiple&#xD;
                  sclerosis OR&#xD;
&#xD;
               -  Currently taking immunosuppressant drugs&#xD;
&#xD;
          2. Have been fully vaccinated against COVID-19 or deemed medically ineligible to receive&#xD;
             full course of vaccine&#xD;
&#xD;
          3. Has documented negative serology/antibody response in an anti-SARS-CoV-2 spike protein&#xD;
             IgG clinical test collected ≤72 hours prior to randomization&#xD;
&#xD;
          4. Tested negative for the COVID-19 virus&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Weighs &lt;40 kg (only applies to participants ≥12 to &lt;18 years of age)&#xD;
&#xD;
          2. Has any signs or symptoms consistent with COVID-19&#xD;
&#xD;
          3. Past COVID-19 infection within 90 days prior to randomization&#xD;
&#xD;
          4. Planned use of any investigational, authorized, or approved vaccine for COVID-19&#xD;
             within 90 days of the last dose of study drug&#xD;
&#xD;
          5. Prior (within 30 days), current, or planned use of any of COVID-19 convalescent&#xD;
             plasma, other monoclonal antibodies against SARS-CoV-2 or any COVID-19 treatment&#xD;
&#xD;
          6. Is planned to begin immunoglobulin (IVIG) or immunoglobulin (SCIG) therapy, is planned&#xD;
             to have a change to existing IVIG or SCIG, or has been on a chronic stable dose of&#xD;
             their IVIG or SCIG regimen for less than 90 days prior to screening&#xD;
&#xD;
          7. Has any known active acute respiratory infection&#xD;
&#xD;
          8. Has persistent (refractory to treatment for ≥14 days) bacterial or fungal infection&#xD;
&#xD;
          9. Has known allergy or hypersensitivity to components of the study drugs&#xD;
&#xD;
        NOTE: Other Protocol Defined Inclusion/Exclusion Criteria Apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trial Management</last_name>
    <role>Study Director</role>
    <affiliation>Regeneron Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trials Administrator</last_name>
    <phone>844-734-6643</phone>
    <email>clinicaltrials@regeneron.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Central Alabama Research</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>205-949-1907</phone>
    </contact>
    <investigator>
      <last_name>Khaleel Ashraf, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>424-315-2861</phone>
    </contact>
    <investigator>
      <last_name>Peter Chen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>650-380-5089</phone>
    </contact>
    <investigator>
      <last_name>Upinder Singh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>916-734-3643</phone>
    </contact>
    <investigator>
      <last_name>Timothy Albertson, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>James R Berenson MD Inc.</name>
      <address>
        <city>West Hollywood</city>
        <state>California</state>
        <zip>90069</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>310-623-1222</phone>
    </contact>
    <investigator>
      <last_name>James Berenson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Thomas Campbell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>North Haven</city>
        <state>Connecticut</state>
        <zip>06473-2195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Midway Immunology and Research Center</name>
      <address>
        <city>Fort Pierce</city>
        <state>Florida</state>
        <zip>34982</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>772-595-9830</phone>
    </contact>
    <investigator>
      <last_name>Moti Ramgopal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Elixia COVID-19</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>954-435-9990</phone>
    </contact>
    <investigator>
      <last_name>Steven Zeig</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AppleMed Research Group, LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>305-667-8434</phone>
    </contact>
    <investigator>
      <last_name>Agustin J. Latorre, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>De La Cruz Research Center, LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33184</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>786-977-6155</phone>
    </contact>
    <investigator>
      <last_name>Alejandro E. De La Cruz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>813-974-1440</phone>
    </contact>
    <investigator>
      <last_name>Kami Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Great Lakes Clinical Trials - Ravenswood</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60625</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>773-275-3500</phone>
    </contact>
    <investigator>
      <last_name>Manish Jain</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>410-614-6702</phone>
    </contact>
    <investigator>
      <last_name>Maria Dioverti-Prono</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>617-735-4436</phone>
    </contact>
    <investigator>
      <last_name>Kathryn Stephenson, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>402-552-2000</phone>
    </contact>
    <investigator>
      <last_name>Diana Florescu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Holy Name</name>
      <address>
        <city>Teaneck</city>
        <state>New Jersey</state>
        <zip>07666</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>201-541-6312</phone>
    </contact>
    <investigator>
      <last_name>Suraj Saggar, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>718-920-2229</phone>
    </contact>
    <investigator>
      <last_name>Margaret McCort, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>212-824-7714</phone>
    </contact>
    <investigator>
      <last_name>Meenakshi Rana, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032-3729</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>212-639-8361</phone>
    </contact>
    <investigator>
      <last_name>Genovefa Papanicolaou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site 2</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Burke Primary Care</name>
      <address>
        <city>Morganton</city>
        <state>North Carolina</state>
        <zip>28655</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>828-391-2024</phone>
    </contact>
    <investigator>
      <last_name>G. Michael Gould, D.O.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Miami Valley Hospital</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45409</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>937-208-2238</phone>
    </contact>
    <investigator>
      <last_name>Thomas Herchline, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Altoona Center for Clinical Research</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>814-693-0300</phone>
    </contact>
    <investigator>
      <last_name>Alan Kivitz, MD, CPI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Penn Prevention Clinical Research Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>215-746-3713</phone>
    </contact>
    <investigator>
      <last_name>Emily Blumberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Temple University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>215-707-1359</phone>
    </contact>
    <investigator>
      <last_name>Gerard Criner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>PharmaTex Research, LLC</name>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <zip>79109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>806-355-2581</phone>
    </contact>
    <investigator>
      <last_name>David Brabham, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Therapeutic Concepts, PA</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>713-526-9821</phone>
    </contact>
    <investigator>
      <last_name>Joseph Gathe Jr., MD, FACP, FIDSA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>713-441-350</phone>
    </contact>
    <investigator>
      <last_name>Howard Huang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>713-745-6263</phone>
    </contact>
    <investigator>
      <last_name>Roy Chemaly, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Synergy Group Medical,LLC</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77087</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>832-532-4210</phone>
    </contact>
    <investigator>
      <last_name>Caroline Mbogua, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jim Boonyaratanakornkit, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin - Madison</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>608-265-0540</phone>
    </contact>
    <investigator>
      <last_name>William Hartman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Cuauhtemoc</city>
        <state>Distrito Federal</state>
        <zip>6700</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Mexico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 8, 2021</study_first_submitted>
  <study_first_submitted_qc>October 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 12, 2021</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-response to COVID-19 vaccination</keyword>
  <keyword>COVID-19</keyword>
  <keyword>Immunocompromised, weakened immune system</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>When Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication, has made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry), has the legal authority to share the data, and has ensured the ability to protect participant privacy.</ipd_time_frame>
    <ipd_access_criteria>Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf</ipd_access_criteria>
    <ipd_url>https://vivli.org/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

